CPC C07K 14/64 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0048 (2013.01); A61K 9/02 (2013.01); A61K 9/10 (2013.01); A61P 11/00 (2018.01); A61P 13/12 (2018.01); C07K 16/1027 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/00 (2013.01); C07K 2319/30 (2013.01)] | 22 Claims |
1. An antibody comprising a light chain comprising light chain complementarity determining regions CDRL1, CDRL2, and CDRL3, and a heavy chain comprising heavy chain complementarity determining regions CDRH1, CDRH2, and CDRH3, wherein:
the CDRL1 comprises the amino acid sequence of SEQ ID NO: 89 (KCQLSVGYMH),
the CDRL2 comprises the amino acid sequence of SEQ ID NO: 90 (DTSKLAS),
the CDRL3 comprises the amino acid sequence of SEQ ID NO: 96 (FQGNGYPFT),
the CDRH1 comprises the amino acid sequence of SEQ ID NO: 72 (TFSGFSLSTSGMSVG),
the CDRH2 comprises the amino acid sequence of SEQ ID NO: 73 (DIWWDDKKDYNPSLKS),
and the CDRH3 comprises the amino acid sequence of SEQ ID NO: 79 (SMITFGGFDV).
|